Analyst Ratings for AbbVie
Portfolio Pulse from Benzinga Insights
AbbVie (NYSE:ABBV) has received 5 somewhat bullish and 1 indifferent rating from analysts in the last quarter, with an average 12-month price target of $177.83, a slight decrease from the previous target of $179.75. Analysts provide ratings based on research and insights into company performance and sector trends.

December 01, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbbVie has a predominantly positive outlook from analysts with 5 somewhat bullish ratings and an average price target of $177.83, reflecting a slight decrease from the previous target.
The somewhat bullish ratings suggest a positive sentiment among analysts, which could be favorable for AbbVie's stock price in the short term. However, the slight decrease in the average price target may temper expectations, leading to a neutral score. The high relevance is due to the direct mention of AbbVie and its analyst ratings. The importance is significant as analyst ratings can influence investor sentiment, but not at the highest level since the ratings are not extremely bullish or bearish. The confidence level is high due to the clear consensus among analysts and the specific data provided.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100